The FDA moved to permanent leadership for CDER and CBER, naming Michael Davis as director of CDER and Karim Mikhail as director of CBER. The continuity push included creating a new Deputy Commissioner role for Technology and Artificial Intelligence, signaling the agency’s intent to formalize technology oversight as AI-enabled products proliferate. This leadership stabilization follows a period of turbulence and high turnover that unsettled industry decision-making, including delays tied to how guidance and internal workflows are administered. Analysts framed the appointment of the interim directors as a step toward easing fears of major policy shifts. For sponsors, the announcement is less about a new policy direction and more about predictable execution—particularly for complex review programs where operational clarity and staffing stability can change practical timelines.